Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (279)	12/5/2003 5:33:57 PM
From: pragat	Respond to of 416

Strategy is all about timing. It appears that this company has tremendous potential-- augmenting sound business fundamentals. In light of the current flu situation, and other potential epidemic outbreaks globally, Medimmune can make a big impact leading to the betterment of public health. The current issue of Money Magazine has discussed Medimmune's value proposition and outlook. Both S&P and Value Line have encouraging ratings: 4*, T2, and S3. Let us hope management capitalizes on the current opportunity, delivers enduring returns to shareholders and employees, monetizes its pipeline (cancer and such), and becomes an industry leader on issues related to public health, epidemiology, and Infectious Diseases.